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Abstract
Background: Neuron specific enolase (ENO2, g-enolase) has been used as a biomarker to help identify
neuroendocrine differentiation in breast cancer. The goal of the present study was to determine if ENO2 expression
in the breast epithelial cell is influenced by the environmental pollutants, arsenite and cadmium. Acute and chronic
exposure of MCF-10A cells to As
+3 and Cd
+2 sufficient to allow colony formation in soft agar, was used to
determine if ENO2 expression was altered by these pollutants.
Results: It was shown that both As
+3 and Cd
+2 exposure caused significant increases in ENO2 expression under
conditions of both acute and chronic exposure. In contrast, ENO1, the major glycolytic enolase in non-muscle and
neuronal cells, was largely unaffected by exposure to either As
+3 or Cd
+2. Localization studies showed that ENO2 in
the MCF-10A cells transformed by As
+3 or Cd
+2 had both a cytoplasmic and nuclear localization. In contrast, ENO1
was localized to the cytoplasm. ENO2 localized to the cytoplasm was found to co-localized with ENO1.
Conclusion: The results are the first to show that ENO2 expression in breast epithelial cells is induced by acute
and chronic exposure to As
+3 or Cd
+2. The findings also suggest a possible link between As
+3 and Cd
+2 exposure
and neuroendocrine differentiation in tumors. Overall, the results suggest that ENO2 might be developed as a
biomarker indicating acute and/or chronic environmental exposure of the breast epithelial cell to As
+3 and Cd
+2.
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Background
This laboratory is interested in the identification of bio-
markers that indicate potential human exposure to
environmental agents. Historically, neuron specific eno-
lase was one of three immunohistochemical markers
that were used to determine tumors that possessed a
subpopulation of tumor cells with neuroendocrine dif-
ferentiation, the other markers being chromogranin A
and synaptophysin [1]. Enolase is an enzyme of the gly-
colytic pathway that catalyzes the conversion of 2-phos-
phoglycerate into phosphoenolpyruvate [2]. In
mammalian tissues, enolase has three tissue-specific iso-
enzymes [3-5]. Enolase molecules are dimers composed
of three distinct subunits coded by separate genes and
originally designed a (liver), b (muscle) and g (brain).
The aa isoenzyme is present in all fetal tissues and
most adult mammalian tissues. The bb-a n dgb-enolase
are found predominantly in skeletal and heart muscle.
The gg-a n dag-enolase are present mainly in nervous
tissue and in tissues with neuroendocrine cells. The gg-
and ag-enolase have been frequently referred to as neu-
ron-specific enolase (NSE), especially when used as a
marker to aid cancer diagnosis and characterization.
The distribution of the enolase isoenzymes has been
determined in normal and malignant human breast by
electrophoresis [6]. In normal human breast tissue the
aa-enolase is the predominant enolase isoenzyme. The
ag- enolase is present in much lower amounts (2-16%),
and the levels of gg-enolase are very low (0 - 3%). A cor-
responding analysis of breast carcinomas shows a distri-
bution of enolase isoenzymes similar to that of normal
breast, but with the proportion of the g-possessing
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immunohistochemistry with an antibody against
g-enolase, no positive staining for g-enolase was found
in several studies employing normal breast tissue [7-10].
In contrast, a high proportion of g-enolase staining cells
was detected in some breast carcinomas [5,7,8,10-16].
The designations ENO1, ENO2, and ENO3 is also com-
monly used in the literature to designate the a, g and b
enolase genes and gene products, respectively.
The extensive studies of neuron-specific enolase
expression in normal breast and breast carcinomas sug-
gested that the breast epithelial cell would be an appro-
priate model on which to determine if arsenite and
cadmium might alter the expression of neuron-specific
enolase. The first goal of the present study was to deter-
mine if acute exposure of MCF-10A cells to As
+3 or Cd
+2 altered the expression of the ENO1 and ENO2 genes.
The second goal of the study was to determine if
chronic exposure to As
+3 or Cd
+2, sufficient to elicit cell
transformation as judged by colony formation in soft
agar, would alter the expression of ENO1 and ENO2.
Results
Immunohistochemical staining of ENO1, ENO2 and ENO3
in normal human breast
The immunohistochemical staining of ENO1, 2 and 3
was determined on 3 archival samples of formalin-fixed,
paraffin-embedded normal human breast tissue. The
staining pattern was similar among all three indepen-
dent tissue samples. Intense staining for ENO1 was
localized to the ductal epithelial and myoepithelial cells
of the breast (Figure 1A, B). The stromal elements of
the breast had moderate to weak staining for the expres-
sion of ENO1. The staining for ENO2 was strong in the
outer myoepithelial cells of the breast ducts (Figure 1C,
D). The stromal elements of the breast were negative
for the expression of ENO2. The ductal epithelial ele-
ments of the breast, when compared to the stroma,
were at or slightly above, background levels of staining.
There was no staining of ENO3 in any cells of the nor-
mal breast (data not shown).
ENO1, 2 and 3 expression in the MCF-10A cell line
T h ee x p r e s s i o no fE N O 1 ,2a n d3m R N Aa n dE N O 1a n d
2 protein were determined on total RNA and protein pre-
pared from confluent cultures of the MCF-10A cell line.
The expression of ENO1 mRNA was detected in MCF-
10A cells at levels similar to that of b-actin mRNA (Fig-
ure 2A). In contrast, the expression of both ENO2 and
ENO3 mRNA was very low and over 100 fold less when
compared to that of ENO1 mRNA in the MCF-10A cell
line (Figure 2A). Western analysis showed that the MCF-
10A cells expressed the ENO1 protein at levels in a large
excess to those found for ENO2 and ENO3. The ENO2
protein was just visible on western analysis (Figure 2B).
The levels of the ENO3 protein were not determined
since there was no evidence of ENO3 mRNA.
ENO 1, ENO2 and ENO3 expression in MCF-10A cells
acutely exposed to Cd
+2 or As
+3
T h ee x p r e s s i o no fE N O 2m R N Aa n dp r o t e i nw e r e
determined in the MCF-10A cells exposed to Cd
+2 and
As
+3 for 48 hrs. Three concentrations of As
+3 (4, 8
and 16 μM) and Cd
+2 (2, 4 and 6 μM) were used and
Figure 1 Immunohistochemistry of ENO1, ENO2 and ENO3 in
Normal Human Breast. Formalin-fixed, paraffin-embedded human
breast biopsy specimens were immunohistochemically stained with
specific antibodies to ENO1 (A and B) or ENO2 (C and D). Color
development was performed via an HRP-linked secondary antibody
with diaminobenzidine as the enzyme substrate, giving light to dark
brown color in regions exhibiting ENO protein expression. ENO1
shows staining in both myoepithelial and epithelial cells of the
breast lobules and ducts whereas ENO2 shows expression mainly in
the myoepithelial cells with a slight staining in the epithelial cells of
breast lobules and ducts. Magnification 100× for A and C; 200× for
B and D.
Figure 2 Expression of ENO-1, -2 and -3 mRNA and protein in
MCF-10A parent cell line. Real-time PCR analysis of ENO-1, -2 and -3
transcript copy number in the MCF-10A parent cell line (A) and
western blot analysis of ENO-1 and -2 in the MCF-10A parent cell line
(B). Transcript copy number was assessed using quantitative DNA
standards and the levels shown are for an RNA input of 40 ng.
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of cell viability following 48 hrs of exposure
(Figure 3A, B). The results showed that both acute
exposure to either As
+3 or Cd
+2 increased the expres-
sion of ENO2 in MCF-10A cells (Figure 2C-H). Expo-
sure of the MCF-10A cells to the lowest level of As
+3
(4 μM) caused a significant increase in ENO2 mRNA
expression following 12 hrs of exposure (Figure 3C).
The two higher concentrations of As
+3 (8 and 16 μM)
elicited a significant increase in ENO2 mRNA expres-
sion following 12 hours of exposure (Figure 3C).
W e s t e r na n a l y s i sf o rE N O 2p r o t e i ne x p r e s s i o nc o n -
firmed the increases in ENO2 mRNA expression
(Figure 3D, E). The ENO2 protein expression could be
noted on the western blots at time points when ENO2
mRNA was just beginning to be elevated following
Figure 3 Expression of ENO-2 mRNA and protein in parental MCF-10A cells exposed to As
+3 and Cd
+2. Cell viability, as an indicator of
cytotoxicity, was determined by measuring the capacity of the MCF-10 cells to reduce MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide) to formazan after exposure to As
+3 (A) and Cd
+2 (B). Real-time RT-PCR analysis of ENO-2 mRNA in parental MCF-10A cells exposed to
As
+3 and Cd
+2 (C and F). Western blot analysis of ENO-2 protein in parental MCF-10A cells exposed to As
+3 and Cd
+2 (D and G) and western
blot densitometric analysis (E and H) respectively. Statistical analysis consisted of ANOVA with Tukey post hoc testing. *Denotes a statistically
significant difference from untreated MCF-10A parent cells (p < 0.05). Real-time data is plotted as the mean ± SEM of triplicate determinations.
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+3.E x p o s u r eo f
the MCF-10A cells to the lowest level of Cd
+2 (2 μM)
resulted in a significant increase in ENO2 mRNA fol-
lowing 12 hrs of exposure, while the two higher
dosages (4 and 6 μM) caused significant increases fol-
lowing 8 hrs of exposure (Figure 3F). The expression
of the ENO2 protein was clearly elevated by 12 hrs of
exposure to all three concentrations of Cd
+2 (3 G, H).
When judged as matched for similar toxicity as shown
by the viability curves, exposure to As
+3 appeared to
be a stronger inducer of ENO2 expression.
The expression of ENO1 mRNA and protein was
determined on identical samples to those described
above. The results showed that for the MCF-10A cells
exposed to As
+3 that there were significant increases in
ENO1 mRNA following 24 hrs of exposure for all three
As
+3 concentrations (Figure 4A). However, these
increases were modest in comparison to those noted for
ENO2 mRNA under identical conditions of exposure.
The increase in ENO1 mRNA expression was accompa-
nied by a trend for increased ENO1 protein expression
but the increases in ENO1 protein were not significant
compared to control (Figure 4B, C). The results showed
that for MCF-10A cells exposed to Cd
+2 that there was
no significant increase in ENO1 mRNA for the 2 lower
Cd
+2 concentrations and at only two time points for the
highest Cd
+2 concentration (Figure 4D). There were no
large increases in ENO1 protein at any of the three
Cd
+2 concentrations with the exception of 6 μMa t3 6
hr (Figure 4E, F). There was no expression above back-
ground for ENO3 mRNA for the MCF-10A cells
exposed to As
+3 or Cd
+2 (data not shown) and for this
reason ENO3 protein was not determined on the
samples.
Transformation of MCF-10A cells with As
+3 and Cd
+2
The transformation of MCF-10A cells with As
+3 and
Cd
+2 followed a protocol very similar to that described
previously by this laboratory for the malignant transfor-
mation of single cultures of UROtsa cells, an immorta-
lized culture of urothelial cells [17-19]. The MCF-10A
cells were exposed to 1 μMA s
+3 or Cd
+2 and each were
monitored by light microscopy 24 hrs before and after
each change of the growth medium and subcultured
when the cells reached confluence. The first assessment
of the cells ability to form colonies in soft agar was per-
formed following the first four serial passages and there-
after every 4 to 5 serial passages. Cells were also
preserved in liquid nitrogen at the time of assessment
for growth in soft agar. At serial passage 25 both sets of
Figure 4 Expression of ENO-1 mRNA and protein in parental MCF-10A cells exposed to As
+3 and Cd
+2. Real-time RT-PCR analysis of ENO-
1 mRNA in parental MCF-10A cells exposed to As
+3 and Cd
+2 (A and D). Western blot analysis of ENO-1 protein in parental MCF-10A cells
exposed to As
+3 and Cd
+2 (B and E) and western blot densitometric analysis (C and F) respectively. Statistical analysis consisted of ANOVA with
Tukey post hoc testing. *Denotes a statistically significant difference from untreated MCF-10A parent cells (p < 0.05). Real-time data is plotted as
the mean ± SEM of triplicate determinations.
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+3 and Cd
+2 transformed cells were able to form
colonies in soft agar (Figure 5A, B, C). At this passage
number, multiple flasks of cells were removed from
liquid nitrogen storage and multiple vials processed for
long-term storage under liquid nitrogen. The light level
morphology of the As
+3 and Cd
+2 transformed cell lines
able to grow in soft agar were very similar to that of
parental MCF-10A cells (Figure 5D, E, F). There was no
evidence at the light level of examination that the cells
had lost the contact inhibition of growth or that they
formed multilayered foci of cells. The doubling time of
both the As
+3 and Cd
+2 transformed cells did decrease
significantly compared to control MCF-10A cells (24.9 ±
0.1, 32.2 ± 0.3, and 39.7 ± 1.6 hrs, respectively).
The As
+3 and Cd
+2 transformed cell lines having the
ability to form colonies in soft agar were each inocu-
lated subcutaneously at a dose of 1 × 10
6 cells at the
dorsal thoracic midline of 5 nude mice to determine if
the cell lines able to form colonies in soft agar were
also capable of forming tumors in immune compro-
mised mice. The mice were assessed every two weeks
for tumor formation and following 9 months of exami-
nation there was no evidence of tumor formation as
noted by the growth of nodules under the skin. The
mice were sacrificed at 9 months and the injection site
under the skin surface examined visually for any evi-
dence of tumor nodules. In no instance was any evi-
dence of tumor formation found in any of the mice.
Extending the serial passages of the MCF-10A cells in
both the presence and absence of As
+3 and Cd
+2 for an
additional 15 passages also had no effect on tumor
formation.
Expression and localization of ENO1 and ENO2 in MCF-
10A cells transformed by As
+3 and Cd
+2
The expression of ENO1 and ENO2 mRNA and protein
were determined on the MCF-10A cell line transformed
by As
+3 and Cd
+2 (Figure 6A-D). The results showed that
the expression of ENO1 mRNA and protein by the MCF-
10A cells transformed with either As
+3 or Cd
+2 was not
altered from that of the parental MCF-10A cell line
(Figure 6A, C). In contrast, it was shown the ENO2
mRNA and protein were increased significantly by the
MCF-10A cells transformed by either As
+3 or Cd
+2 when
compared to the parental MCF-10A cells (Figure 6B, D).
Immunofluorescence was used to localize the expres-
sion of ENO1 and ENO2 in the MCF-10A parental cells
and their As
+3 and Cd
+2 transformed counterparts. In
all three cell lines, the intracellular localization of ENO1
was diffuse within the cytoplasm with only a very minor
fraction of total cellular ENO1 localized to the nuclear
region (Figure 7A-C). This pattern was found consis-
tently throughout the cell population and there were no
differences observed in ENO1 staining intensity or intra-
cellular distribution among the three cell lines. In all
three cell lines, the intracellular localization of ENO2
was characterized by both diffuse, punctate cytoplasmic
staining and by substantial levels of staining localizing
to the nuclear region (Figure7 D - F ) .A l lt h r e ec e l ll i n e s
Figure 5 Soft agar and light microscopic morphology of MCF-
10A parent cells, before and after malignant transformation.
Soft agar and light microscopic morphology of control MCF-10A
cells (A and D), As
+3- transformed MCF-10A cells (B and E) and Cd
+2- transformed MCF-10A cells (C and F) respectively. Growth rates
and doubling times of control MCF-10A cells and MCF-10A cells
after malignant transformation with As
+3 or Cd
+2 (G and H)
respectively. Soft agar and light microscopy pictures taken at 200 ×
and 100 × magnifications respectively.
Figure 6 Expression of ENO-1 and ENO-2 mRNA and protein in
As
+3 and Cd
+2- transformed MCF-10A cells. Real-time RT-PCR
and western blot analysis of ENO-1 mRNA and protein in As
+3 and
Cd
+2- transformed MCF-10A cells (A and C) and ENO-2 (B and D)
respectively. Statistical analysis consisted of ANOVA with Tukey post
hoc testing performed using GraphPad PRISM 5. *Denotes a
statistically significant difference from MCF-10A parent cells (p <
0.05). Real-time data is plotted as the mean ± SEM of triplicate
determinations.
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sity within the cell population. In contrast to the trans-
formed cell lines, many profiles of parental MCF-10A
cells were either negative for the expression of ENO2 or
had low levels, particularly within the cytoplasm. Visual
observation of fluorescence intensity also suggested that
the As
+3 and Cd
+2 transformed cell lines have higher
levels of ENO2 compared to parental cells. This differ-
ence is very evident in the merged images of ENO1 and
ENO2 staining (Figure 7G-I). These images also show
an overlap within the cytoplasm of ENO1 and ENO2
localization as well as an overlap of predominately
ENO2 with the nucleus.
The co-localization of ENO1 and ENO2 was also deter-
mined among the cell lines by capturing optimal z-series
confocal slices of 0.46 μm. These images were examined
as single slices (Figure 8A-C) as well as orthogonal views
of the z-series through the x- and y-planes (Figure 8D-I).
Co-localization of ENO1 and ENO2 was demonstrated in
the cytoplasm of cells from all three cell lines. There were
also instances of cells in all three cell lines that were
observed to have little to no co-localization of ENO1 and
ENO2. However, co-localization of ENO1 and ENO2 was
observed in a high proportion of fields of all captured
cells. Co-localization appeared to be dependent on the
levels of ENO2, with cells having higher levels of cytoplas-
mic ENO2 being more likely to show co-localization with
ENO1. When comparing the As
+3 and Cd
+2 transformed
cells to the parent MCF-10A cells, ENO1 and ENO2 were
observed to not only co-localize in a higher number of
cells within the population of the transformed cell lines
but to also have more co-localization within individual
cells than that of the parent cell line. This difference is
most likely simply due to there being substantially more
ENO2 in the As
+3 and Cd
+2 transformed cell lines. Possi-
ble co-localization within the nucleus could not be deter-
mined due to the very low levels of ENO1 in the nucleus.
The images in the above Figures provide evidence that
ENO2 can be localized in the cell nucleus. Further evi-
dence was obtained by staining for ENO2 followed by
treating the cells with To-PRO-3 iodide. Optimal z-ser-
ies confocal slices of 0.46 μm were captured and exam-
ined as both single slices as well as orthogonal views of
the z-series through the x- and y-planes (Figure 9). The
results showed that ENO2 staining was closely asso-
ciated with the nucleus (Figure 9A-C). In the orthogonal
views, results show ENO2 staining within the nucleus
structure itself (Figure 9D-I). The ENO staining also
tended to cluster in regions of the nucleus that had low
To-PRO-3 iodide staining. This may indicate that ENO2
associates with euchromatin versus the more intensely
staining heterochromatin.
ENO2 mRNA expression in parental MCF-10A cells
following treatment with inhibitors of DNA methylation
and acetylation
The MCF-10A parental cell line was treated with the
histone deacetylase inhibitor, MS-275, and the
Figure 7 Localization of enolase-1 and -2 in the MCF-10A cell
lines. Cells were stained for enolase-1 (red) shown in A-C and for
enolase-2 (green) shown in D-F. These confocal images were taken
through the z-series and then the z-plane images were stacked
together to form the image shown. Therefore, each image represents
the total cellular enolae-1 or -2 staining within each field.
Subsequently, the enolase-1 and -2 images were then merged
together along with the epifluorescent image of the DAPI nuclear stain
(blue) and are shown in G-I. The field of MCF-10A As
+3 transformed
cells are shown in A, D, and G: the field of MCF-10A Cd
+2 transformed
cells are shown in B, E, and H; and the non-transformed MCF-10A
parent cells are shown in C, F, and I. Bar = 10 μm.
Figure 8 Co-localization for enolase-1 and -2. Cells were stained
for enolase-1 (red) and then for enolase-2 (green). Co-localization is
shown in the cytoplasm (yellow) for the As
+3 transformed (A, D, G),
Cd
+2 transformed (B, E, H) and parent MCF-1-A (C, F, I) cells. Single
z-series slices of 0.46 μm are shown in A-C with orthogonal slices of
the z-series shown for the x-axis in D-F and the y-axis in G-I. The
bar indicates the scale for images in A-C; bar = 5 μm.
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role of epigenetic modifications on ENO2 mRNA
expression. This analysis demonstrated that treatment of
the cells with either MS-275 or 5-AZC significantly
increased the expression of ENO2 mRNA compared to
control cells (Figure 10A, B). The samples utilized were
generated in a previous study and the concentrations
and times used resulted in no cell death [20].
Discussion
The expression and localization of ENO1, ENO2 and
ENO3 was determined on three archival samples of nor-
mal human breast tissue to determine if the antibody
used in the present study produced results in agreement
with past reports in the literature. Immunostaining for
ENO1 showed all the cells of the normal breast to have
expression of ENO1. This is in agreement with the lit-
erature which reports the ubiquitous expression of
ENO1 in adult tissues and cells [6,21,22]. Immunostain-
ing for ENO2 showed the myoepithelial cells of the nor-
mal breast to have strong staining for ENO2. This
pattern of expression is in agreement with an earlier
study on ENO2 expression in normal human tissues
other than the nervous system [5]. This finding is also
in agreement with the finding of ENO1/ENO2 and
ENO2 isoenzymes in extracts of human breast tissue
that were analyzed using electrophoresis [6]. It is very
possible that the expression of ENO2 found in this past
report was from the myoepithelial cells of the breast
and not from the ductal epithelial cells. However, the
present immunostaining studies of ENO2 in the normal
breast could not rule out a very low expression of
ENO2 at or near background levels in the breast epithe-
lial cells. Consistent with the literature, immunostaining
showed no expression above background for ENO3 in
the normal human breast [6]. The analysis of ENO1, 2
and 3 mRNA and protein expression in the MCF-10A
cell line was in agreement with the immunostaining
results found in the normal breast. This study showed
that the MCF-10A cell line had a high level of ENO1
expression in both mRNA and protein. ENO2, however,
was expressed at a considerably lower level with western
analysis barely detecting the protein on gels. Analysis if
ENO3 mRNA expression was near the detection limit of
the PCR assay, and the protein expression was not ana-
lyzed further due to the absence of appreciable mRNA
expression. Immunofluorescent localization showed all
cells to expression ENO1 protein and a much lower per-
centage of cells to express ENO2 protein and when pre-
sent, a much lower intensity of expression. Overall,
these findings confirmed that the MCF-10A cells mod-
eled the expression of ENO1, 2 and 3 similar to that
found in the epithelial cells of the normal breast.
To the authors knowledge there has been no examina-
tion of the effect that exposure to Cd
+2 or As
+3 has on
the expression of enolase in the breast epithelial cell or
other epithelial cell types. The enolases do have a metal
requirement for activity, and six divalent metal ions,
magnesium, manganese, zinc, cadmium, cobalt and
nickel, can activate enolase [21]. However, these metals
are required for enzyme activity and none of the six
divalent metals has been shown to increase the expres-
sion of any of the enolases at the level of mRNA or pro-
tein. The demonstration in the present study that acute
exposure to either As
+3 or Cd
+2 increases the expression
of ENO2 mRNA and protein is the first to suggest a
role of these metals in the elevation of neuron specific
enolase in the breast epithelial cell and possibly other
Figure 9 Localization of enolase-2 to the nucleus. Cells were
stained for enolase-2 (green) followed by staining for the nuclei
with To-PRO-3 iodide (red). Localization within the nucleus is shown
for the As
+3 transformed (A, D, G), Cd
+2 transformed (B, E, H) and
parent MCF-10A (C, F, I) cells. Single z-series slices of 0.46 μm are
shown in A-C with orthogonal slices of the z-series shown for the x-
axis in D-F and the y-axis in G-I. The bar indicates the scale for
images in A-C; bar = 5 μm.
Figure 10 Real-time RT-PCR analysis of ENO-2 mRNA levels in
parental MCF-10A cells treated with epigenetic regulators.
Figure 10 (A) shows expression of ENO-2 mRNA after treatment
with histone deacetylase Inhibitor, MS-275 for up to 72 hrs and (B)
shows expression of ENO-2 mRNA after treatment with the DNA
demethylation agent, 5-AZC, for 24 hrs. Statistical analysis consisted
of ANOVA with Tukey post hoc testing performed using GraphPad
PRISM 5. *Denotes a statistically significant difference from
untreated MCF-10A parent cells (p < 0.05). Real-time data is plotted
as the mean ± SEM of triplicate determinations.
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+3 and Cd
+2 is specific for the acute induction of ENO2
expression is strongly suggested by the finding that
identical exposure resulted in only a limited induction
of ENO1 mRNA and no induction of ENO1 protein and
no increase in ENO3 mRNA. These findings suggest
that ENO2 expression might be translated as a possible
biomarker for acute environmental exposure to either
As
+3 or Cd
+2.
The properties of ENO1 have been studied in far
greater detail than that of ENO2, even though ENO2
has been employed extensively as a tumor marker for
neuroendocrine differentiation. The finding that ENO2
is specifically induced by As
+3 and Cd
+2 in the breast
epithelial cell calls into question how much of the accu-
mulated knowledge known for ENO1 can be translated
to the ENO2 isoform. It is known that ENO1 is a multi-
functional protein and has functions beyond that of its
central role in glycolysis [21]. ENO1 is expressed on the
surface of a variety of eukaryotic cells as a strong plas-
minogen-binding receptor. This has been shown for
hematopoietic cells, epithelial cells, and endothelial cells
[21,22]. The mechanism by which ENO1 reaches the
cell surface is unknown. In addition, ENO1 has also
been shown to have an alternative protein form known
as the Myc-binding protein, MBP-1 [21,23]. The start
codon for MBP-1 ATG resides 400 bp downstream of
the ENO1 ATG and thus is considered to be an alterna-
tive translation initiation product of ENO1 mRNA. In
endothelial cells, ENO1 has been shown to be a hypoxic
stress protein. The possible role of ENO1 in various dis-
ease states has also received far greater study than that
of ENO2 [21]. Many of these possible roles are related
to the surface expression of ENO1 and plasminogen
binding since this may play an important role in modu-
lating the pericellular and intravascular fibrinolytic sys-
tem. It does not appear that similar studies have been
undertaken for the ENO2 isoform, and it is unknown if
the properties known for ENO1 protein are also present
for ENO2. The only caveat is that this laboratory’s ana-
lysis of the ENO2 mRNA sequence showed no evidence
of an alternative initiation site that could specifically
encode the MBP-1 Myc-binding protein.
The MCF-10A cell line was transformed by exposure
to As
+3 and Cd
+2 to determine if this would result in
altered expression of ENO2 mRNA and protein. Pre-
vious studies have shown that the MCF-10A cell line
can be transformed by exposure to Cd
+2 [24], but this
has not been shown previously for As
+3. In the present
study, transformation was judged to have occurred
when the As
+3 and Cd
+2 exposed MCF-10A cells were
able to produce colonies in soft agar. The ability for col-
ony formation in soft agar is typical of cancer cells and
is thought to reflect anchorage-independent growth of
tumor-initiating/cancer stem cells [25,26]. The As
+3 and
Cd
+2 transformed cell lines were unable to form tumors
when inoculated subcutaneously in immune compro-
mised mice. This may be due to the site of inoculation,
since the earlier study showing the transformation of
MCF-10A cells with Cd
+2, the cells were injected under
the renal capsule [24], a technique not available at this
laboratory’s animal facility. The current study showed
that the expression of ENO2 was significantly elevated
in both As
+3 and Cd
+2 transformed cell lines compared
to parent MCF-10A cells with the As
+3-transformed
cells having higher expression than that of the Cd
+2-
transformed cells. ENO1 expression was not altered in
these cells. Similar to that found for acute exposure,
these findings suggest that ENO2 expression might be
translated as a possible biomarker for chronic environ-
mental exposure to either As
+3 or Cd
+2. The elevated
expression of ENO2 in the As
+3 and Cd
+2 transformed
cell lines allowed an analysis of the intracellular localiza-
tion of ENO2 as well as its interaction with ENO1. It
was shown in these cell lines that ENO1 has a diffuse,
mainly cytoplasmic localization while ENO2 displays
both a punctate, cytoplasmic localization and a nuclear
localization. The cytoplasmic ENO1 and ENO2 were
s h o w nt oc o - l o c a l i z e .T h e r ew a sn oe v i d e n c eo fa n y
nuclear ENO1 localization or any ENO1 co-localization
with nuclear ENO2. There does not appear to be pre-
vious literature reports of nuclear ENO2 localization in
human epithelial cancer cells. ENO2 has been shown to
localize to the nucleus of olfactory neurons in young
animals [27] and in the glioblastoma cell line GM7 [28].
Olfactory neurons that had ENO2 localized to the
nucleus, were from young animals, while in adults,
ENO2 was exclusively localized to the cytoplasm. In the
As
+3 and Cd
+2 transformed MCF-10A cells, ENO2 fre-
quently localized to regions of the nucleus that had low
levels of the nuclear stain To-PRO-3 iodide, a profile
which might indicates a preferred localization to regions
of euchromatin. Although ENO2 mRNA does not
appear to have the alternate initiation site that codes for
MBP-1, a protein which localizes to the nucleus, there is
substantial homology between MBP-1 and the corre-
sponding region in ENO2.
As detailed in the Introduction, immunostaining with
ENO2, chromogranin A and synaptophysin have been
used extensively to determine neuroendocrine differen-
tiation in breast cancer. As a prognostic indicator, an
immunostaining profile suggestive of neuroendocrine
differentiation in breast cancer has been shown to have
limited utility to enhance patient diagnosis or predict
outcome [29-32]. However, there is evidence to suggest
that ENO2 is altered in breast cancer even though its
expression may not have independent prognostic value.
Gene expression analysis has shown ENO2 mRNA to be
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pared to primary breast tumors [33] and ENO2 mRNA
to be upregulated in the estrogen receptor positive sub-
set of 36 invasive ductal breast carcinomas [34]. The
findings in the present report that ENO2 expression in
MCF-10A cells may be influenced by both methylation
and histone modifications may provide a link between
ENO2 expression in the breast epithelial cell and altera-
tions in epigenetic gene regulation by the environmental
pollutants, arsenic and cadmium. The earlier report doc-
umenting the malignant transformation of MCF-10A
cells by Cd
+2 strengthens the evidence for a role for Cd
+2 in the development of breast cancer and also provides
an extensive literature review on the available evidence
linking breast cancer with exposure to Cd
+2 [24]. The
evidence for a role of As
+3 in the etiology of breast can-
cer is far more limited with a major consideration being
its ability, similar to Cd
+2,t of u n c t i o na sa ne n d o c r i n e
disruptor [35,36]. Thus, the present study shows that
acute and chronic exposure of MCF-10A cells to both
As
+3 and Cd
+2 induces the expression of ENO2 and that
the effects of As
+3 and Cd
+2 on ENO2 expression may
be at the level of epigenetic modification.
Conclusions
This study shows that the expression of the ENO2 gene
in the breast epithelial cell can be induced by acute
exposure to either As
+3 or Cd
+2 as well as by chronic
exposure sufficient to allow colony formation of the
cells in soft agar. Evidence is presented that control of
ENO2 gene expression is controlled by methylation and
histone modification.
Methods
Immunostaining for ENO1 and 2 in normal breast
Tissue sections for the immunohistochemical analysis of
ENO1 and 2 expression in human breast were obtained
from archival paraffin blocks that originated from pre-
viously completed patient diagnostic procedures. These
archival specimens contained no patient identifiers and
use was approved by the University of North Dakota
Internal Review Board. Tissues were routinely fixed in
10% neutral buffered formalin for 16-18 hours. All tis-
sues were transferred to 70% ethanol and dehydrated in
100% ethanol. Dehydrated tissues were cleared in xylene,
infiltrated, and embedded in paraffin. Tissue sections
w e r ec u ta t3 - 5μm for use in immunohistochemical
protocols. Prior to immunostaining, sections were
immersed in preheated citrate buffer pH 6.0 and heated
in a steamer for 20 minutes. The sections were allowed
to cool to room temperature and immersed into Tris
buffered saline with Tween 20 (Dako, Carpinteria, CA)
for 5 minutes. The primary antibody for the localization
of ENO1 (Abcam Inc., Cambridge, MA, Cat # Ab54979)
was used at a 1:400 dilution and for ENO2 (Abcam Inc.,
Cambridge, MA, Cat # Ab54979) was used at a 1:250
dilution. Liquid diaminobenzidine was used for visuali-
zation. Slides were rinsed in distilled water, dehydrated
in graded ethanol, cleared in xylene, and coverslipped.
Cell culture
The MCF-10A cell line was obtained from the American
Type Culture Collection and grown in a 1:1 mixture of
Ham’s F-12 medium and DMEM supplemented with 5%
(v/v) fetal calf serum, 10 μg/ml insulin, 0.5 μg/ml hydro-
cortisone, 20 ng/ml epidermal growth factor, and 0.1
μg/ml cholera toxin. The cells were fed fresh growth
medium every 3 days, and at confluence (normally 6-12
days post subculture), the cells were subcultured at a
1:10 ratio using trypsin-EDTA (0.25%, 1 mM). Prelimin-
ary experiments were performed to determine the
approximate concentrations of Cd
+2 and As
+3 that
would be at or below that resulting in MCF-10A cell
toxicity over an acute time course of exposure. From
this preliminary determination, 3 concentrations of
CdCl2 (2, 4 and 6 μM) and 3 concentrations of NaAsO2
were chosen for a short-term exposure of 48 hrs. Cell
viability and growth curves were determined by measur-
ing the capacity of the cells to reduce MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
to formazan [37]. Triplicate cultures were analyzed for
each time point and concentration.
Cadmium- and arsenite-induced transformation of MCF-
10A cells
The protocol used to transform the MCF-10A cell line
with Cd
+2 and As
+3 has been detailed previously for
the human bladder UROtsa cell line [17]. An identical
protocol starting with the parental MCF-10A cell line
was used in the present study. Briefly, cultures of
MCF-10A cells were grown to confluency in 25 cm
2
cell culture flasks and when confluent, each of the
flasks were fed fresh growth media containing 1 μM
As
+3 (NaAsO2, Fluka #71287) or 1 μMC d
+2 (CdCl2,
Sigma, St. Louis, MO). Following addition of the Cd
+2
and As
+3, the cultures were thereafter fed fresh growth
media every three days that contained As
+3 or Cd
+2.
The cultures were observed immediately before and 24
hrs after each feeding by light microscopy and subcul-
tured at confluence.
The cultures were tested every 4 to 6 serial passages
for their ability to form colonies in soft agar using a
slight modification of the procedure described by San
and coworkers [17,38]. Briefly, 60 mm diameter dishes
were prepared with a 5 ml underlay of 0.5% agar in
DMEM containing 5% fetal calf serum. On top of the
under layer was placed 2 × 10
4 cells in 1.5 ml of 0.25%
agar in DMEM containing 5% fetal calf serum. The
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atmosphere inside humidified plastic containers to pre-
vent evaporation. Cultures were examined microscopi-
cally 24 hrs after plating to confirm an absence of large
clumps of cells and thereafter at 7, 14 and 21 days after
plating. The respective cultures that showed colony for-
mation in soft agar along with the MCF-10A parent cell
line, were each inoculated subcutaneously (s.c.) at a
dose of 1 × 10
6 cells in the dorsal thoracic midline of 5
nude (NCr-nu/nu) mice. Tumor formation and growth
were assessed weekly. All mice were sacrificed 9 months
following injection. All experimental procedures with
the use of mice were approved by the University of
North Dakota Institutional Animal Care and Use Com-
mittee and conform to the National Research Council’s
Guide for the Care and Used of Laboratory Animals.
Areas where the cells were injected were paraffin-
embedded, sectioned, stained with Hematoxylin and
Eosin (H&E), and analyzed by light microscopy.
Expression of ENO1, ENO2 and ENO3 mRNA and protein
in the MCF-10A and MCF-10A derived cell lines
The procedures used for the preparation of total RNA
and protein from cultured cells has been described pre-
viously by the laboratory [17,39]. The expression of
ENO1, ENO2 and ENO3 mRNA was determined using
real time RT-PCR and ENO1, 2 and 3 specific primers
obtained from Qiagen (Valencia, CA). The levels of
ENO1, 2 and 3 mRNA was determined relative to the
MCF-10A cells using ENO-1, 2 and 3 standards to gen-
erate a standard curve. The expression levels of ENO-1,
2a n d3w e r en o r m a l i z e dt ob-actin. The results are
expressed in copy number/1000 b-actin transcripts and
plotted as % change. The expression of ENO1 and 2
protein was determined by western blotting using 20 μg
of total cellular protein on a 12.5% SDS-polyacrylamide
gel using the above ENO1 and 2 antibodies at 1:100,000
and 1:2,000 dilutions, respectively. Anti-mouse IgG
HRP-linked Ab was used to detect ENO-1 and anti-rab-
bit IgG, HRP-linked Ab used to detect ENO-2. The bio-
tinylated molecular weight marker was detected with
anti-biotin-HRP-linked antibody. The blots were visua-
lized using the phototope-HRP western blot detection
system.
Immunolocalization of ENO1 and ENO2 in the MCF-10A
and MCF-10A-derived cell lines
The cell lines were grown in 24 well plates containing
12 mm glass coverslips at 37°C, 5% CO2. Cells at a
nearly confluent density were then fixed and stained
according to published protocols [18,19]. Briefly, cells
were fixed in 3.7% buffered, methanol-free formaldehyde
(Polysciences, Inc, Warrington, PA) for 15-20 minutes
at room temperature. Coverslips were then quenched of
free aldehyde with 0.1 M NH4Cl for 15 minutes, fol-
lowed by permeabilization with 0.1% Triton-X100 for 10
minutes. Cells were stained for ENO1 (primary and sec-
ondary antibodies) followed by staining for ENO2. Stain-
ing for ENO1 or ENO2 was carried out by incubation
for 45-60 minutes at 37°C with 0.5 μg/ml of mouse
anti-ENO1 or a 1:100 dilution of rabbit anti-ENO2 anti-
body. Primary antibodies were detected by incubating
cells with 2.7 μg/ml of Alexa-Fluor 594 goat anti-mouse
IgG or 2.7 μg/ml of Alexa-Fluor 488 goat anti-rabbit
antibody (Invitrogen, Carlsbad, CA) for 45-60 minutes
at 37°C. Controls consisted of coverslips treated with
the appropriate secondary antibody(ies) only, staining
f o rE N O 1o rE N O 2a l o n ew i t ha p p r o p r i a t em o u s eo r
rabbit secondary antibodies as well as with in-appropri-
ate rabbit or mouse secondary antibodies, respectively.
All controls stained appropriately and negative controls
had virtually no staining when photographed under the
same settings that were used for experimental cells. For
experiments determining the localization of ENO2 to
the nucleus, ENO2 staining was carried out as indicated
above followed by staining with a 5 μM solution of To-
PRO-3 iodide (Invitrogen) for 30 minutes at 37°C. All
coverslips were mounted in ProLong Gold anti-fade
reagent with DAPI (Invitrogen) for nuclear counter
staining. Cells were observed and images captured using
a Zeiss LSM 510 Meta Confocal Microscope with LSM
510 software (Carl Zeiss MicroImaging Inc). Images
were obtained by capturing z-slices at a depth of 0.46
μm. DAPI images of the same fields were captured by
epifluorescence.
Treatment of MCF-10A cells with 5-Azacytidine and
histone deacetylase inhibitor MS-275
The MCF-10A cells were seeded at a ratio of 1:10 and
the next day they were exposed to 0.5 and 1.5 μM5 -
azacytidine (AZC) or the histone deacetylase inhibitor
MS-275 at 1.0, 3.0, and 10 μM for three days till the
cells reached confluency as described previously [20].
Cells were then harvested for the determination of
ENO2 mRNA expression.
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